Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment
-
Published:2024-08-28
Issue:9
Volume:12
Page:1958
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Yapislar Hande1, Gurler Esra Bihter2ORCID
Affiliation:
1. Department of Physiology, Faculty of Medicine, Acibadem University, 34752 Istanbul, Türkiye 2. Department of Basic Sciences, Faculty of Dentistry, Istanbul Galata University, 34430 Istanbul, Türkiye
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels, which can lead to severe health issues if not managed effectively. Recent statistics indicate a significant global impact, with 463 million adults diagnosed worldwide and this projected to rise to 700 million by 2045. Type 1 diabetes is an autoimmune disorder where the immune system attacks pancreatic beta cells, reducing insulin production. Type 2 diabetes is primarily due to insulin resistance. Both types of diabetes are linked to severe microvascular and macrovascular complications if unmanaged. Microvascular complications, such as diabetic retinopathy, nephropathy, and neuropathy, result from damage to small blood vessels and can lead to organ and tissue dysfunction. Chronic hyperglycemia plays a central role in the onset of these complications, with prolonged high blood sugar levels causing extensive vascular damage. The emerging treatments and current research focus on various aspects, from insulin resistance to the intricate cellular damage induced by glucose toxicity. Understanding and intervening in these pathways are critical for developing effective treatments and managing diabetes long term. Furthermore, ongoing health initiatives, such as increasing awareness, encouraging early detection, and improving treatments, are in place to manage diabetes globally and mitigate its impact on health and society. These initiatives are a testament to the collective effort to combat this global health challenge.
Reference162 articles.
1. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Martin, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci., 21. 2. The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives;Chan;Lancet,2021 3. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030;Wild;Diabetes Care,2004 4. Martinez-Ortega, A.J., Munoz-Gomez, C., Gros-Herguido, N., Remon-Ruiz, P.J., Acosta-Delgado, D., Losada-Vinau, F., Pumar-Lopez, A., Mangas-Cruz, M.A., Gonzalez-Navarro, I., and Lopez-Gallardo, G. (2022). Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia. J. Clin. Med., 11. 5. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes;Riddle;Diabetes Care,2021
|
|